Genmab to take at least one new product to phase III in 2021
Genmab is boosting investments in the company's pipeline, and aside from supporting current star candidates, the investments are meant to lead one more product – at least – to late-stage trials, according to CEO Jan van de Winkel.
ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Last year, when Genmab presented its annual financial report, the firm predicted that it would need an additional DKK 1bn (USD 163.7m), at least, to spend on its development.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab appoints chief medical officer
For subscribers
.jpg&w=384&q=75)
